Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Burkitt's Lymphoma
- Sponsor
- Gachon University Gil Medical Center
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Event-free survival
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Detailed Description
Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis
Investigators
Junshik Hong
Assistant Professor, Department of Internal Medicine
Gachon University Gil Medical Center
Eligibility Criteria
Inclusion Criteria
- •pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria
- •age \>20 yrs
- •received rituximab+chemotherapy as first-line treatment
- •with measurable or evaluable lesion
Exclusion Criteria
- •patients with BL or BL-U previously treated with rituximab
Outcomes
Primary Outcomes
Event-free survival
Time Frame: one year
Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)
Secondary Outcomes
- complete response rate(1-year)
- overall survival(1-year)
- Grade 4 hematologic toxicities(one year)